Provided by Tiger Fintech (Singapore) Pte. Ltd.

Shattuck Labs, Inc.

2.14
+0.350019.55%
Post-market: 2.150.0100+0.47%17:16 EDT
Volume:549.43K
Turnover:1.10M
Market Cap:102.51M
PE:-1.77
High:2.15
Open:1.81
Low:1.76
Close:1.79
52wk High:3.95
52wk Low:0.6922
Shares:47.90M
Float Shares:24.15M
Volume Ratio:0.81
T/O Rate:2.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2083
EPS(LYR):-1.4857
ROE:-73.39%
ROA:-41.95%
PB:1.80
PE(LYR):-1.44

Loading ...

Company Profile

Company Name:
Shattuck Labs, Inc.
Exchange:
NASDAQ
Establishment Date:
2016
Employees:
44
Office Location:
500 West 5th Street,Suite 1200,Austin,Texas,United States
Zip Code:
78701
Fax:
- -
Introduction:
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. The company was incorporated in 2016 and is headquartered in Austin, Texas.

Directors

Name
Position
George Golumbeski
Independent Chairman of the Board
Taylor Schreiber
Chief Executive Officer and Director
Clay Siegall
Independent Director
Daniel Baker
Independent Director
Helen M. Boudreau
Independent Director
Mona Ashiya
Independent Director
Neil Gibson
Independent Director

Shareholders

Name
Position
Taylor Schreiber
Chief Executive Officer and Director
Andrew R. Neill
Chief Financial Officer
Abhinav Shukla
Chief Technical Officer
Arunthathy Nirmalini Pandite
Chief Medical Officer
Casi DeYoung
Chief Business Officer
Stephen Stout
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer